Optometry; dissolves TPA-Formulary and TPA-Formulary Committee.
SB1081 revises Virginia’s optometry statutes to eliminate the separate TPA-Formulary Committee and to dissolve the TPA-Formulary structure as a distinct committee-based process. The bill amends the optometry chapter to preserve and restate the authority of TPA-certified optometrists to prescribe and administer certain therapeutic pharmaceutical agents, including limited controlled substances and topical drugs, for diseases and abnormal conditions of the eye and its adnexa. It also retains the existing limits on optometric treatment, such as restrictions on surgery, invasive modalities, infantile or congenital glaucoma treatment, and the narrow emergency use of epinephrine for anaphylactic shock.
The bill updates the regulatory framework so that the Board of Optometry, rather than a standing TPA-Formulary Committee, controls the formulary and related treatment guidelines through regulation. The Board must still hold a public hearing before amending the formulary or treatment guidelines, provide notice, and publish proposed and final changes, but the committee that previously recommended formulary drugs is removed. Related conforming changes are made to the controlled substances and prescription provisions so that TPA-certified optometrists remain expressly authorized prescribers for the limited drugs on the formulary.
In practical terms, the bill affects the scope of practice for optometrists, the Board of Optometry, the Board of Pharmacy, and the Board of Medicine, while also affecting pharmacists and drug distributors who supply formulary drugs. It preserves optometrists’ ability to prescribe a narrow set of ocular therapeutics, including hydrocodone-acetaminophen, certain oral analgesics, topical Schedule VI drugs, and intramuscular epinephrine, while shifting the administrative mechanism for updating the list of allowable drugs from a committee to the board itself.
The overall sentiment reflected in the voting history was strongly favorable and noncontroversial. The bill advanced unanimously through the Senate and House, with no recorded dissenting votes at any stage. That pattern suggests broad agreement on the need to streamline the formulary process while maintaining the existing scope of optometric therapeutic authority.
No major points of contention are reflected in the available record. The main policy issue embedded in the bill is whether the formulary should continue to be shaped by a multi-profession committee or instead be managed directly by the Board of Optometry through regulation. Because the bill passed unanimously, any concerns about professional oversight, patient safety, or scope-of-practice expansion were either resolved before floor action or were not significant enough to generate opposition.
SB1081 amends Virginia Code §§ 54.1-3222, 54.1-3223, 54.1-3301, and 54.1-3303 to remove the TPA-Formulary Committee and make the TPA-formulary a board-managed regulatory function. It preserves the authority of TPA-certified optometrists to prescribe and administer specified therapeutic pharmaceutical agents and makes conforming changes to the controlled-substances and prescription statutes so optometrists remain recognized prescribers for the limited drugs authorized under the formulary. The bill primarily affects the Board of Optometry’s rulemaking authority, while also affecting optometrists, pharmacists, wholesalers, and other drug suppliers involved in dispensing formulary medications.
The bill appears to have been received positively and without significant opposition. It passed the Senate and House unanimously, and the committee votes recorded in the history were also unanimous. That voting pattern indicates broad bipartisan support and little visible controversy around the restructuring of the optometry formulary process.
The only notable policy issue is the shift from a seven-member TPA-Formulary Committee, which included optometrists, pharmacists, and ophthalmologists, to direct Board of Optometry control over the formulary and treatment guidelines. Supporters likely viewed this as a streamlining or modernization measure, while any critics would have been concerned about reducing multi-profession oversight or changing how therapeutic drugs are added to the formulary. However, the unanimous votes suggest those concerns did not produce organized opposition in the legislative process.